| Log in

Fresenius comes with delisting offer for Indian arm, may cost up to $72M

18 April, 2013

German healthcare firm Fresenius SE & Co. KGaA has made a delisting offer for its Gurgaon-based pharmaceutical arm Fresenius Kabi Oncology Ltd, to acquire the entire public shareholding of around 19 per cent. The move may cost the company as much as Rs 390 crore ($72 million).

Fresenius owns 81 per cent in the firm and has to comply with the minimum public listing norms, which call for at least 25 per cent free float of a company’s stock. This has to be met by June 30, 2013. Fresenius would either need to dilute its holding or delist the company to comply with the regulations.

For delisting, it needs to cross the 90 per cent threshold, which will cost around Rs 190 crore.

Fresenius Kabi Pte Ltd, the Singapore arm of the healthcare company, has offered to purchase the rest of the public shareholding of the company, around 30 million shares, at an indicative price of Rs 130 per unit.

Fresenius Kabi Oncology’s scrip declined 1.6 per cent and was trading at Rs 132 a share at 3 pm on Thursday in a strong Mumbai market.

Fresenius had acquired around 73.23 per cent stake in Dabur Pharma from Burman family for Rs 878 crore in 2008. Dabur Pharma, which produced anti-cancer drugs, was then rebranded to Fresenius Kabi Oncology. Fresenius raised its stake through the open offer triggered by change in management control back then. It had offered to buy shares at Rs 76.5 a unit at that time.

(Edited by Sanghamitra Mandal)


Leave Your Comment
Parenteral Drugs to sell Goa unit to Fresenius Kabi for $36.8M

Parenteral Drugs to sell Goa unit to Fresenius Kabi for $36.8M

Bhawna Gupta 5 years ago
Public-listed Parenteral Drugs India Ltd has entered an agreement with Fresenius...
Honeywell Auto, Fresenius Kabi May Queue Up For Delisting

Honeywell Auto, Fresenius Kabi May Queue Up For Delisting

Boby Kurian 7 years ago
Honeywell Automation India Ltd and oncology drug maker Fresenius Kabi, formerly...
IFC Makes A Modest 41% Return Over Three Years From Dabur Pharma

IFC Makes A Modest 41% Return Over Three Years From Dabur Pharma

Pallavi S 9 years ago
Normal 0 MicrosoftInternetExplorer4 st1:*{behavior:url(#ieooui) } <!&;*/ /...
No Comments

Fresenius comes with delisting offer for Indian arm, may cost up to $72M

Powered by WordPress.com VIP